Roche claims clinical success against breast cancer
Keystone-SDA
Swiss pharmaceutical giant Roche has achieved positive results from the phase III evERA study combining its experimental treatments giredestrant and everolimus against a specific form of breast cancer.
The combination of the two substances, administered orally, resulted in a “significant” increase in the survival time of patients without disease progression, compared with the current standard of treatment consisting of endocrine therapy and everolimus.
+Get the most important news from Switzerland in your inbox
In its press releaseExternal link on Monday, the Swiss multinational stated that it did not at this stage have mature data on the total survival rate of patients with locally advanced or metastatic oestrogen receptor-positive (ER+) and human epidermal growth factor receptor-negative breast cancer who had already undergone prior treatment.
The adverse side effects observed were comparable to those of the two substances administered separately.
More
More
How a clash with Roche exposed cracks in Switzerland’s drug pricing system
Roche points out that it is running no fewer than five clinical programmes on combinations of giredestrant in breast cancer. The substance is designed to prevent oestrogens from binding to their receptors, thereby interrupting or slowing the progression of cancer cells.
Adapted from French by DeepL/ac
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch
